![]() Be alert to hypokalemia or hyperglycemia. ![]() ![]() Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis or unusually responsive to sympathomimetic amines.Instruct patients to contact a healthcare provider immediately if symptoms occur Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction. Worsening of urinary retention may occur.Consider referral to an ophthalmologist in patients who develop ocular symptoms or use BREZTRI long term. Worsening of narrow-angle glaucoma may occur, so use with caution. Glaucoma and cataracts may occur with long-term use of ICS.Assess initially and periodically thereafter in patients at high risk for decreased bone mineral content Decreases in bone mineral density have been observed with long-term administration of ICS.Use caution in patients with cardiovascular disorders, especially coronary insufficiency, as formoterol fumarate can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles.Discontinue and consider alternative therapy Anaphylaxis and other hypersensitivity reactions (eg, angioedema, urticaria or rash) have been reported.If paradoxical bronchospasm occurs, discontinue BREZTRI immediately and institute alternative therapy.Adverse effects related to increased systemic exposure to budesonide may occur Caution should be exercised when considering the coadministration of BREZTRI with long-term ketoconazole and other known strong CYP3A4 Inhibitors.If such changes occur, consider appropriate therapy Hypercorticism and adrenal suppression may occur with regular or very high dosage in susceptible individuals.Taper patients slowly from systemic corticosteroids if transferring to BREZTRI ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |